Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration-Reference-Cited by-同舟云学术

Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration

Published:2016-02-19 Issue:2 Volume:36 Page:225-241
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Wheeler Graham M.¹,Sweeting Michael J.²^ORCID,Mander Adrian P.¹^ORCID,Lee Shing M.³,Cheung Ying Kuen K.³

Affiliation:

1. MRC Biostatistics Unit Hub for Trials Methodology Research Cambridge Institute of Public Health Forvie Site, Robinson Way Cambridge CB2 0SR U.K.

2. Cardiovascular Epidemiology Unit, Strangeways Research Laboratory University of Cambridge Cambridge CB1 8RN U.K.

3. Department of Biostatistics, Mailman School of Public Health Columbia University 722 West 168th Street New York NY 10032 U.S.A.

Funder

Medical Research Council

American Cancer Society

European Research Council Advanced Investigator Award: EPIC-Heart

UK Medical Research Council

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.6912

Reference21 articles.

1. NCI.Common Terminology Criteria for Adverse Events v4.0. NCI NIH DHHS National Cancer Institute 2009. Available from:http://evs.nci.nih.gov/ftp1/CTCAE/[Accessed on 8 January 2016].

2. Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

3. Strategies for optimizing combinations of molecularly targeted anticancer agents

4. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and ϵ-tapering;The Annals of Applied Statistics;2022-09-01

2. Flexible use of copula‐type model for dose‐finding in drug combination clinical trials;Biometrics;2021-08

3. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents;Biometrical Journal;2018-05-28

4. Early phase dose finding methodology;Statistics in Medicine;2016-12-06